Compare Kraft Heinz Co (KHC) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Eli Lilly And Co — how do they compare? Kraft Heinz Co trades at $22.29 (market cap $26.66B), while Eli Lilly And Co trades at $1,177.77 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 39× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (7.12%). Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Eli Lilly And Co for 93 Days on average.
| KHC | LLY | |
|---|---|---|
Market Cap | $26.66B | $1.04T |
Volume | 31,300,109 | 3,064,878 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $1.28K |
52-Week Low | $21.21 | $799.57 |
Typical Hold Time | 129 Days | 93 Days |
Enterprise Value | $42.98B | $1.09T |
Dividend Yield | 7.12% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.27, up 1.32% today, with a bearish technical signal but positive earnings beats in recent quarters. The company faces fundamental headwinds, including a net loss of $5.85 billion in 2025 and a negative net income margin of -13.64%, though operating cash flow remains strong at $4.46 billion. Recent news highlights turnaround efforts, such as new product launches and a $700 million reinvestment plan, amid a high dividend yield and mixed analyst sentiment.
The outlook is cautious due to profitability challenges and high debt, but the stock's low valuation (P/E of 13.04, P/B of 0.74) and consistent cash flow offer potential for value investors. Risks include sustained volume declines and competitive pressures, while the consensus price target of $24.50 suggests modest upside if turnaround initiatives gain traction.
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
